Guarantee the compensation committee retained a 3rd party such as McKinsey or another compensation consultant to opine if the plan is reasonable and at the market.
Truly believe it and buying more......
As much as many here bash the CEO, the real value of ARRY are the molecules it has an economic interest and the fact real third parties, namely AstraZeneca and Novartis are conducting phase 3 trials.
Dude, the CEO does not approve the compensation plan - the compensation and executive committee's present to the full board and they approve the plan!!
Biotech companies have virtually no correlation to a global economic slowdown, the risk one faces is the binary outcomes of clinical trials.
If he is forced to rule, my guess is neither side wins but rather he splits the baby down the middle and Brady gets 2 games. No hard evidence on the Goodell side, but you don't need hard evidence in a civil matter, an abundance of circumstantial evidence is enough. On the Brady side, judges and courts are highly suspicious of those who destroy evidence during an investigation (watch out Hillary!!).
I think they should settle and take the SEC route. Brady should not admit to or deny the allegations and settle for a monetary fine and that is it - no suspension. That way both sides can save face.
Brady really screwed up at the very beginning. He should have just said I like my footballs on the soft side of the legal limit and whatever the equipment guys did with them was their choice. Admit that you communicated to them you like it on soft side of legal and it would have been done with. Perhaps a fine against the team and actions against the equipment personnel. The fact he didn't go down this route suggests some level of guilt....
Live near Foxboro too.....
Interesting action. Follow up trade of over 600 contracts at the $6 strike Dec calls. More interesting, someone bought 1207 contracts for $0.15 at the $10 strike call for September and another 1000 contracts for $0.10 at the $11 strike, again in September. Obviously, buying these out-of-the money calls in the near month someone hoping for a buyout or something. The data at the European conference will not be presented until after the September calls expire......
Someone also bought 7,805 December 2015 call options $6 strike for $1.20. The bet is the stock will be above $7.20 by December just to break-even........
The investment thesis has little to do with CEO Squarer and everything to do with the molecules they have an economic interest. Even better, ARRY has low participation in the clinical trials - AstraZeneca running one with Novartis running the other. Yes, they do have some early development molecules they control but these are early days. We have some very strong molecule prospects with real companies taking them through real trials. In some ways, a donkey could be running the company, and perhaps we have one, but ultimately the value of this company will flow through the molecules and very little will come from the CEO. (Although our CEO/company does need to negotiate a distribution/manufacture agreement with a European partner by year-end).
The street analysts covering ARRY all have Buy ratings with price targets ranging from $9 to $14.50 over next 12 months. These price targets incorporate very high discount rates given the risk inherent with a binary outcome in terms of the trial outcomes. However, if the molecule progresses from phase 3 to NDA, the discount rates fall and the price targets rise. This stock looks like a double to triple from this level in my opinion.....
A $2-3 Billion portfolio - $15 -$20 stock by year-end.
I have no idea where you are getting the $0.14. If you take their presentation off their website and look at the pro forma data associated with their recent acquisitions and the net impact on refinance of their debt, you get a potential pick-up in the dividend of $0.06 - $0.07, to $0.29 - $0.30, assuming a constant payout ratio of about 85% of FFO. My guess is they have left some dry powder so they can increase the dividend again and/or keeping some extra capital available to help fund acquisitions. They could also be negotiating with banks for some form of revolving credit lines to improve financial flexibility to fund future acquisitions. Keeping a lower payout ratio may be comforting to the banks from a credit perspective. This is a growth through acquisition vehicle and story at the end of the day in a highly attractive fragmented industry.
They announced at time of last dividend that future dividends would be announced at same time of earnings
Dividend will be announced at same time 2nd quarter earnings are released likely to be early August, not July.
Dude, you have no idea what you are talking about. You want this company to make acquisitions that yield NOI of 6.5%!! The reason the dividend is going up in the second quarter is due to the recent $435 MM purchase that was accretive to the equity!! The company will pay-out an industry standard of about 85% of normalized FFO. Based on the pro forma results they reported for the 1Q, the is will result in the dividend being raised to $0.28 - $0.30 for the second quarter. They may opt for a lower payout ratio this quarter and continue to build over the course of the year. They will report 2Q and dividend roughly 1st or 2nd week of August. My guess is they go out the end of the year at $0.35 dividend, or possibly higher. At $0.35, or $1.40 annualized and a 5.5% rate, this gets you a $25 stock price.
If we do an accretive large acquisition in the rest of this year, the stock could go even higher. Lastly, SNR could become a very attractive acquisition candidate for Ventas, HCP, Brookdale, etc. given it's size.
The 6.5% NOI yield the company quotes is net of management fee paid to FIG. You should also note that the management team at SNR gets paid $0 - FIG pays them as FIG employees. If we paid our CEO/CFO and all others from FIG market rates of compensation, I am sure it exceeds the management fee they are earning now.
In terms of how SNR trades, take a look at the ownership table, a lot of REIT index products own a lot of SNR. After SNR was spun out, the stock traded up to over $20, I am sure this was driven by the index funds that had to own the shares regardless of price. The good news is when we have to issue equity for future acquisitions, we have a natural buyer, the index funds.
Lastly, our interests as SNR shareholders are aligned with FIG. This is a core business for Fortress, creating companies and value. If people lost money on all their deals, Fortress would have no business. Of course, Fortress also owns just under 5% of the company directly.
My guess is we will hear of another large deal for SNR in the not so distant future and they will need to issue more equity to finance. They already have a debt conduit lined up based on their latest refi. SNR/FIG will build this up to a $1.50 - $1.60 annualized divvy by the end of 2015. Assuming a 5.5% yield, gives you a share price in the high 20's by year-end. Risk-adjusted, given the stability of the cash flows, this will be a very attractive return.
You have no idea what you are talking/writing about - you obviously do not know what you own. SNR is an acquisition driven REIT. The $435 MM recent acquisition is a fantastic transaction earning a 6.5% NOI yield on a leveraged basis. It's accretive in terms of cash flow and allows the company to keep raising the divvy. They will do more deals and issue equity as each deal comes along. They have a pipeline of over $2 B of potential acquisition candidates. The recent deal plus the refinance of the debt will result in a meaningful increase in the divvy. HC REITs trade around 5-6% and its trading right in the middle at 5.5%. My estimate is the stock migrates closer to $23 over next 4-6 months once the 2Q divvy is posted while holding a 5.5% yield. The rule of thumb is each acquisition is about $0.10 accretive for every $100 MM of equity they issue in an acquisition assuming about 30-40% equity, remainder debt and a NOI of 6.5%
This is an acquisition vehicle and we are just about in the 2nd inning. The company has reached a level of scale and now has access to public markets that the banks are comfortable lending at under 3% against the asset portfolio. As a result, the company's scale and ability to finance using a blended cost of capital of around 4% at 50/50 debt/equity creates an arbitrage relative to the acquisition market if you can buy at a yield of 6-8%. Any improvement in occupancy, efficiencies and/or pricing enhances the arbitrage. They could also finance with more debt and widen the arbitrage as well, but at some point too much debt, compresses the trading multiple.
It will be interesting to see as the company matures if they complement the acquisition strategy with a build - my guess is that will a few years in the future.
Just listened to last call and reviewed their presentations. Near term over next there months, it looks like we have about $0.20 NFFO upside, if not more, based on debt refi and $435 MM acquisition. I bet there is another acquisition right after this one. It also sounds like there is another $0.10 of upside from efficiency gains. My guess we go out of 2015 with a quarterly divvy of around $0.33 - $0.35. At a 5.5% yield, that implies a $24 - 26 share price from here. This is all before any new acquisitions - I smell a double in this one........
Good point on TRGP. My guess is they bit off quite a lot with APL and it will take some time to integrate before they do another acquisition.
You can make a case of a Cohen discount on ARP. Arguably, ARP has among the best assets for a GP/LP structure yet it trades at over 13%. The coal-bed methane assets and the Rangely Field oil assets are long-lived slow decline assets. You could also say the same for the Barnett gas shallow assets but just not that profitable at this gas price. The fast decline Utica, Marcellus and Mississippi Lime fields make the most sense for the syndicate business. So overall, a nice mix of assets.
My guess is once commodity prices start to rise, the Cohen discount will start to narrow. I actually think they did the right thing taking down the distribution to $1.30. They have reset expectations lower, not incorporated any savings on the service side in their numbers even though they are realizing the savings currently, and lowered the bar for the syndicate raise in 2015. Furthermore, higher distribution coverage should result in a lower trading yield over time. No much has to go right to create a positive surprise.
Management is re-loading all of their incentive plans at ATLS at this lower price in the $8s. They have a huge incentive to get the IDRs back in the money over the next year. This is why I am reloading down here - after Friday I'm up to 150,000 units and plan to keep buying more.....
Despite the over-promising, the Cohen's have actually delivered among the best returns to the GP's in the entire MLP space. I made a boatload when they sold to Chevron and then reformed the GP with ARP & APL as the LP's and I loaded up at around $8 in the old ATLS. It was a four-bagger over 4 years. Selling APL to TRGP turned out to be a brilliant move. Imagine if ATLS still controlled APL over last few months - old ATLS would not have ended at $32 but probably all the way back to $8 given the amount of capital APL needs. The one thing I do know, own what the Cohen's own and that is the GP. I am loading up again at $8 in the new ATLS. From here, you don't even need the Cohen's to do anything, all you need is the commodity price to recover half of what it has lost to double your money.
I agree with the sentiment that GP/LP structure is not optimal for an E&P company with depleting assets with the constant need for capital. At some point, the Cohen's will use the value of the GP to acquire assets to drop down into ARP. I also suspect they will try to get more involved with ARCX in the storage business to take advantage of contango in the oil markets. I wouldn't be surprised if they somehow found a way into the pipeline business again. They will not sit on their hands as this opportunity set caused by commodity price decline opens up.
Globally, look at the price of Brent to WTI, it's widened out to $10 from $0 in January. This tells me we just have a logistics and production problem in US. A year from now, production will be about 8.3 MM BBD vs. 9.3 today. We will be talking about shortages!!
Lastly, hold onto your TRGP. It won't be around until the end of the year. My guess is either Kinder, Enterprise or Williams will buy it. All three have enormous cost of capital advantage relative to TRGP. Plus TRGP just created a huge tax asset with the purchase of APL. Would not be surprised if TRGP got bought at $140 in 2015.
The GP trading at a higher yield than the LP makes absolutely no sense. This places no value on the GP IDRs. They may not be earning on the IDRs, we are only $0.30 annually at ARP from the IDRs being fully in the money. Therefore, an option value is warranted for the IDR exposure now. Furthermore, the GP puts up absolutely no capital for full control of the LP and also benefits when the LP uses capital for accretive activities such as acquisitions. Lastly, if the commodity price recovers only half of what it has declined in the last 6 months, ARP's distribution will rise by 50% but ATLS will go up by 100%.
This is why all GPs trade at a lower yield than their underlying LPs.
At the end of February, ATLS issued Series A Convertible Preferred to Leon Cooperman and Management for $40 MM Cash. The shares are convertible at a minimum of $8, or based on a trailing average trading level over 30 days. Cooperman and management appears to have little incentive for the shares/units to trade much above $8 until the end of March. Terms of the preferred look very favorable - a sweetheart piece of paper with an escalating coupon starting at 10% I believe. Unfortunately, depending how the cash proceeds were used, our common units were diluted by this piece of paper by an estimated 15%. Put another way, I believe our distributions would be more like $0.85 - $0.95 had this paper not been issued.
Given Cooperman's support for the company and his 15% ownership stake, I am not that offended by the dilution attributed to him. Management on the other hand is more troubling.
At the end of the day, both ARP and ATLS are a call option on rising commodity prices.